Workflow
CytoSorbents Provides DrugSorb-ATR Regulatory Update
Prnewswire· 2025-09-16 19:00
Accessibility StatementSkip Navigation PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today provided a regulatory update on DrugSorbâ"¢-ATR. On August 20, 2025, the Company announced that it had received a U.S. Food and Drug Administration (FDA) appeal decision regarding the FDA's previous denial letter of the Company's De Novo applicat ...
GSP Commences Field Investigations to Advance Alwin Mine and Mer Property Porphyry Targets
Thenewswire· 2025-09-16 19:00
勘探活动启动 - 公司动员现场团队前往Alwin矿区和Mer矿区 针对近期识别出的与斑岩矿化源一致的地球物理异常进行跟进调查 [1] - 2025年秋季地表勘探计划包括岩石地球化学采样和地质蚀变填图 旨在为未来钻探靶区开发提供依据 [2] - 在Mer矿区将完成土壤地球化学网格测量 以更好界定铜钼矿化潜在范围(图1) [2] 地球物理发现 - NSAMT地球物理调查在Alwin矿区深部界定出一个导电异常 该异常位于西北走向的斑岩相关蚀变带内 [3] - 导电异常区域附近的历史钻孔发现斑岩型铜矿化带 其中08-062钻孔见矿9.7米 铜品位0.55% [4] - 1969年钻探曾揭露可能导电的滑石-高岭石蚀变Bethsaida相侵入岩 [4] 矿区开发进展 - Mer矿区位于Alwin西北2.5公里处 已向不列颠哥伦比亚省矿业与关键金属部提交5年期多区域基础许可申请 [5] - 许可申请旨在为第一阶段钻探计划做准备 历史冲击钻探曾界定出斑岩铜钼矿带 见矿段包括30米铜品位0.53% [5] - 公司全资拥有Alwin铜金银矿权和Mer矿权 以及Olivine Mountain矿权(其中60%权益已授予第三方期权) [9] 技术验证 - 技术信息经APEX Geoscience Ltd首席顾问Kristopher J Raffle(BC省注册地质师)审查批准 符合NI 43-101标准 [7] - 图1显示Mer与Alwin矿权位置位于Highland Valley铜矿带 [6] - 矿化真实宽度尚未确定 [12]
Capitan Silver Strengthens Management Team and Board with Key Hires
Newsfile· 2025-09-16 19:00
Capitan Silver Strengthens Management Team and Board with Key HiresSeptember 16, 2025 7:00 AM EDT | Source: Capitan Silver Corp.Vancouver, British Columbia--(Newsfile Corp. - September 16, 2025) - Capitan Silver Corp. (TSXV: CAPT) ("Capitan" or the "Company") is pleased to announce several additions to the Company's management team and Board of Directors.New appointments and additions to the Capitan team include:Graham Scott, DirectorMarc Idziszek, promoted to Vice President of ExplorationIsra ...
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
Globenewswire· 2025-09-16 19:00
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual F ...
Laurion Strengthens Its Board With Appointment of Vikram Jayaraman as a New Director
Thenewswire· 2025-09-16 19:00
Toronto, ON – September 16, 2025 – TheNewswire - LAURION Mineral Exploration Inc. (TSX.V: LME; OTC: LMEFF) (“LAURION” or the “Corporation”) is pleased to announce the appointment of Mr. Vikram Jayaraman, MBA, M.Eng., to its Board of Directors, effective immediately.Vikram has served on LAURION’s Technical Advisory Board since December 2022, where he provided technical support through his role at DRA Americas Inc., particularly in evaluating processing options for LAURION’s surface stockpiles and facilitati ...
Dryden Gold Corp. Announces Marketing Agreement and Grant of Stock Options
Newsfile· 2025-09-16 19:00
Dryden Gold Corp. Announces Marketing Agreement and Grant of Stock OptionsSeptember 16, 2025 7:00 AM EDT | Source: Dryden Gold Corp.Vancouver, British Columbia--(Newsfile Corp. - September 16, 2025) - Dryden Gold Corp. (TSXV: DRY) (OTCQB: DRYGF) (FSE: X7W) ("Dryden Gold" or the "Company") The Company is pleased to announce that it has extended its engagement with Bunt Capital Corporation ("Bunt") announced on March 7, 2025. Bunt is a full-service marketing and consulting services company focus ...
Verisk Launches Generative AI Commercial Underwriting Assistant to Revolutionize Risk Assessment and Underwriting Efficiency
Globenewswire· 2025-09-16 19:00
New cloud-based solution automates workflows and enhances commercial underwriting expertiseJERSEY CITY, N.J., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, today announced the launch of its Commercial GenAI Underwriting Assistant, a cloud-based solution designed to modernize commercial property underwriting. Powered by Verisk’s advanced data analytics and generative AI, this solution enables underwriters ...
Meta Connect 2025: AI-powered smart glasses take center stage
CNBC· 2025-09-16 19:00
Meta CEO Mark Zuckerberg tries on Orion AR glasses at the Meta Connect annual event at the company's headquarters in Menlo Park, California, U.S., September 25, 2024. REUTERS/Manuel OrbegozoMeta spent billions of dollars unsuccessfully trying to make virtual reality catch on with consumers. As it shifts its metaverse bet toward smart glasses, investors will be watching to see how the public responds.The social media company is set to unveil its most advanced smart glasses yet on Wednesday at its Connect ann ...
Surge Announces Letter of Intent with Evolution Mining Limited to Enter into a Joint Venture Agreement
Newsfile· 2025-09-16 19:00
Surge Announces Letter of Intent with Evolution Mining Limited to Enter into a Joint Venture AgreementSeptember 16, 2025 7:00 AM EDT | Source: Surge Battery Metals Inc.West Vancouver, British Columbia--(Newsfile Corp. - September 16, 2025) - Surge Battery Metals Inc. (TSXV: NILI) (OTCQX: NILIF) (FSE: DJ5) (the "Company" or "Surge") is pleased to announce that it has entered into a non-binding letter of intent ("LOI") with Evolution Mining Limited ("Evolution"), pursuant to which the parties wi ...
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
Prnewswire· 2025-09-16 19:00
Accessibility StatementSkip Navigation SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updates on enrollment progress, U.S. site expansion, and expected data readouts from the ongoing GOBLET trial evaluating pelareorep in gastrointestinal cancers. The study is supported in part by a grant from the Pancreatic Cancer Action Network (PanCAN). "The GOBLET trial is desi ...